版本:
中国

BRIEF-Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda

May 17 Syndax Pharmaceuticals Inc

* Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda (pembrolizumab) for the treatment of advanced melanoma

* 31% objective response rate for first stage of phase 2 melanoma cohort of ENCORE 601

* ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC patients progressed on or after anti-PD1 therapies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐